New dosing of ddI (Videx) and Nelfinavir (Viracept) approved.
Highleyman
L
L
D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016049:Didanosine / Q000008:administration & dosage* / Q000009:adverse effects; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D019888:Nelfinavir / Q000008:administration & dosage*; D010195:Pancreatitis / Q000139:chemically induced; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019888:Nelfinavir; D016049:Didanosine